Grifols, S.A.

GRFS

Healthcare Drug Manufacturers General

Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.

Revenue
+9.37%
EPS
+59.8%
Free cash flow
+4.11%
Total debt
−6.08%

Quarter to September 2026, against a year earlier

8.43 0.03 −0.35%
Market cap
$2.2B
P/E
18.2×
Fwd P/E
—
Dividend yield
1.12%
F-score
5/9
ROIC
4.76%
Net debt / EBITDA
5.2×
Dividend safety
54/100

Grifols, S.A. (GRFS) P/E ratio

Alert me on P/E ratio

As of 6 November 2026, Grifols, S.A. (GRFS) trades at a P/E ratio of 18.2×. Over the past ten years it has ranged from 8.8× (December 2021) to 59.2× (December 2023); the current reading is higher than 29% of that period. That is below the Drug Manufacturers General industry median of 26.5× and below the Healthcare sector median of 24.5×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 20.2× (4.44%)
FY2024 21.2× (62.61%)
FY2023 56.6× 123.53%
FY2022 25.3× 23.56%
FY2022 20.5× 3.65%
FY2021 19.8× 9.03%
FY2021 18.1× 2.77%
FY2020 17.6× (14.36%)
FY2020 20.6× 1.33%
FY2019 20.3× 10.42%

Quarterly newest first

Period P/E ratio Change
Sep 2026 15.8× (8.85%)
Mar 2026 17.3× (14.22%)
Dec 2025 20.2× (18.47%)
Sep 2025 24.8× 10.18%
29 more quarters

Against its own ten years

Low 8.8× High 59.2×
Ten-year median 19.9×
Current reading's percentile 30

P/E ratio against peers

Company P/E ratio
AMRN Amarin Corporation PLC compare n/m
NVO Novo Nordisk A/S compare 10.1×
BMY Bristol Myers Squibb Company compare 13.7×
GSK GSK PLC Sponsored ADR compare 16.7×
OGN Organon & Co. compare 17.3×
GRFS Grifols, S.A. 18.2×
SNY Sanofi compare 23.3×
BIIB Biogen Inc. compare 105×
NSRX Nasus Pharma Ltd. compare —
Drug Manufacturers General industry median 26.5×
Healthcare sector median 24.5×
Market median 17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on GRFS